Suppressing Pancreatic Cancer Survival and Immune Escape via Nanoparticle-Modulated STING/STAT3 Axis Regulation
Bioconjugate Chemistry · 2024
DOI: 10.1021/acs.bioconjchem.4c00379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2024. Verfasst von Rui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Canter, Peking University, Beijing 100871, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Pancreatic Neoplasms, Membrane Proteins, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, State Key Program of National Natural Science of China.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) poses a challenge in oncology due to its high lethality and resistance to immunotherapy. Recently, emerging research on the stimulator of interferon gene (STING) pathway offers novel opportunities for immunotherapy. Although STING expression is retained in PDAC cells, the response of PDAC cells to STING agonists remains ineffective. Signal transducer and activator of transcription 3 (STAT3), a downstream pathway of STING, is notably overexpressed in pancreatic cancer and related to tumor survival and immune escape. We observed that inhibiting STAT3 signaling post-STING activation effectively suppressed tumor growth through signal transducer and activator of transcription 1 (STAT1)-mediated apoptosis but led to a potential risk of immune-related adverse events (irAEs). To address this issue, we designed a tumor-penetrating liposome for the codelivery of STING agonist and STAT3 inhibitor. These nanoparticles regulated the STING/STAT3 signaling axis and effectively inhibited the proliferation and survival of tumor. Simultaneously, we found a significant increase in the activation of NK cells and CD8+ T cells after treatment, leading to robust innate immunity and adaptive immune response. We highlight the potential of regulating the STING/STAT3 axis as a promising treatment for improving clinical outcomes in PDAC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Canter, Peking University, Beijing 100871, China.
- Department of Ultrasound, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
- Department of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310027, China.
- Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China.
- School of Environment, Harbin Institute of Technology, Harbin 150001, China.
ORCID-Profile: Rui Li, Renfa Liu, Zhifei Dai
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- State Key Program of National Natural Science of China
- the Key Project of International Cooperation of National Natural Science Foundation
Zitieren
APA
Li, R., Liu, R., Xu, Y., Zhang, S., Yang, P., Zeng, W., Wang, H., Liu, Y., Yang, H., Yue, X., & Dai, Z. (2024). Suppressing Pancreatic Cancer Survival and Immune Escape via Nanoparticle-Modulated STING/STAT3 Axis Regulation. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.4c00379
Vancouver
Li R, Liu R, Xu Y, Zhang S, Yang P, Zeng W, et al. Suppressing Pancreatic Cancer Survival and Immune Escape via Nanoparticle-Modulated STING/STAT3 Axis Regulation. Bioconjugate Chemistry. 2024. doi:10.1021/acs.bioconjchem.4c00379
BibTeX
@article{Li2024,
author = {Li, Rui and Liu, Renfa and Xu, Yunxue and Zhang, Shuhao and Yang, Peipei and Zeng, Wenlong and Wang, Huiyang and Liu, Yijia and Yang, Huajing and Yue, Xiuli and Dai, Zhifei},
title = {Suppressing Pancreatic Cancer Survival and Immune Escape via Nanoparticle-Modulated STING/STAT3 Axis Regulation},
journal = {Bioconjugate Chemistry},
year = {2024},
doi = {10.1021/acs.bioconjchem.4c00379}
}
EUVIMED